Skip to content

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers

A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Single Ascending Dose Study to Asses the Safety, Tolerability, Pharmacokinetics of AZD1446 Including an Open Food Effect Panel in Healthy Male and Non-Fertile Female Volunteers

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00803855
Acronym
SAD
Enrollment
110
Registered
2008-12-08
Start date
2008-12-31
Completion date
2009-04-30
Last updated
2009-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

single dose, pharmacokinetics, safety, healthy volunteers, food interaction, AZD1446

Brief summary

The primary purpose of this study is to assess the safety and tolerability of AZD1446 following single dose administration.

Interventions

oral, single dose

Sponsors

AstraZeneca
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* physical healthy volunteers * weight between 50 to 100 kg and a body mass index (BMI) between 19 and 30 kg/m2

Exclusion criteria

* History of any clinically significant disease or disorder. * History of severe allergy/hypersensitivity reactions

Design outcomes

Primary

MeasureTime frame
Safety and tolerability of AZD1446 by assessment of serious adverse events, ECGs, vital signs and laboratory variablesFrom first to last visit

Secondary

MeasureTime frame
Determine the single ascending dose pharmacokinetics of AZD1446PK sampling taken at defined timepoints during residential period
Determine the single dose of AZD1446 on food interactionFrom first to last visit

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026